Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
4/29/2026, 12:00:00 AM
Announced on 2026-04-29 that its B7-H3 targeted ADC, HS-20093, was granted Breakthrough Therapy Designation by China's NMPA for treating advanced castration-resistant prostate cancer. Medium importance is assigned as Breakthrough Therapy Designation is a significant milestone likely impacting price by >=5%.
Korean Translation
2026-04-29에 자체 개발 B7-H3 표적 ADC HS-20093이 진행성 거세 저항성 전립선암 치료용으로 중국 국가약품감독관리국(NMPA)으로부터 혁신치료제 지정을 받았음을 발표함. 혁신치료제 지정은 중요한 이정표로 5% 이상의 주가 영향이 예상되어 'Medium'으로 분류함.
Related Recent Events
WuXi Biologics (Cayman) Inc (2269) · Other
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
12/18/2026, 12:00:00 AM
Sonova Holding AG (SOON) · Other
On June 16, 2026, the Annual General Meeting 2026 is scheduled; low impact expected as it is a routine corporate event, scheduled.
6/16/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
Medtronic is scheduled to report its financial results for the fourth quarter and full fiscal year 2026 on June 3, 2026. This event is expected to have a medium impact as earnings reports typically drive significant price volatility scheduled.
6/3/2026, 12:00:00 AM
Hangzhou Tigermed Consulting Co Ltd (3347) · Other
Annual General Meeting scheduled for June 2, 2026, to vote on the 2025 profit distribution plan, a final dividend of RMB 1.26 per 10 shares, and a general mandate for the board to repurchase H-shares. Routine AGM and dividend announcement are likely to cause a price impact of 1% or more, scheduled.
6/2/2026, 12:00:00 AM
Sonova Holding AG (SOON) · Earnings Release
On May 18, 2026, publication of the full-year results for the 2025/26 fiscal year is scheduled. The company expects growth to be at the lower end of guidance; high impact expected as earnings are a key market driver, expected.
5/18/2026, 12:00:00 AM
WuXi AppTec Co Ltd (2359) · Other
Ex-dividend date on May 13, 2026, for the 2025 final cash dividend of RMB 1.57927 per share (RMB 15.7927 per 10 shares); low impact estimated as price typically adjusts by the dividend amount, scheduled.
5/13/2026, 12:00:00 AM